{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:00:53Z","timestamp":1792555253576,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.yexcr.2021.112633","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T02:58:39Z","timestamp":1622602719000},"page":"112633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2"],"prefix":"10.1016","volume":"406","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lile","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2021.112633_bib1","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/jcp.29126","article-title":"Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers","volume":"235","author":"Aghebati-Maleki","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2021.112633_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/acs.bioconjchem.9b00669","article-title":"Recent advances in molecular imaging with gold nanoparticles","volume":"31","author":"Bouche","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib3","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1002\/jcp.29789","article-title":"Recent advances in the antilung cancer activity of biosynthesized gold nanoparticles","volume":"235","author":"Wang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2021.112633_bib4","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/jcb.27415","article-title":"Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases","volume":"120","author":"Aghaie","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2021.112633_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8090347","article-title":"Emerging nanopharmaceuticals and nanonutraceuticals in cancer management","volume":"8","author":"Salama","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.yexcr.2021.112633_bib6","doi-asserted-by":"crossref","first-page":"102037","DOI":"10.1016\/j.cis.2019.102037","article-title":"Gold nanoparticles: new routes across old boundaries","volume":"274","author":"Kumari","year":"2019","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.yexcr.2021.112633_bib7","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s10637-011-9767-5","article-title":"Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients","volume":"30","author":"Villarroel","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.yexcr.2021.112633_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ijc.28362","article-title":"Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity","volume":"134","author":"Chen","year":"2014","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.yexcr.2021.112633_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijpharm.2018.03.023","article-title":"Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: an approach for improved oral pharmacokinetics of Sorafenib","volume":"542","author":"Khan","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.yexcr.2021.112633_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ejmech.2019.06.070","article-title":"Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib11","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1016\/j.bmc.2017.09.003","article-title":"Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold","volume":"25","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.bmc.2018.03.039","article-title":"Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf(V600E) and VEGFR-2","volume":"26","author":"Sun","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"Teleanu","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yexcr.2021.112633_bib14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.yexcr.2021.112633_bib15","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2174\/1389557516666160321114917","article-title":"Review on EGFR inhibitors: critical updates","volume":"16","author":"Singh","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib16","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/vco.12107","article-title":"VEGFR-2 expression in malignant tumours of the canine mammary gland: a prospective survival study","volume":"14","author":"Santos","year":"2016","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.yexcr.2021.112633_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23010024","article-title":"Design and discovery of quinazoline- and thiourea-containing sorafenib analogs as EGFR and VEGFR-2 dual TK inhibitors","volume":"23","author":"Sun","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.yexcr.2021.112633_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.colsurfb.2012.10.046","article-title":"Gelatin-nanogold bioconjugates as effective plasmonic platforms for SERS detection and tagging","volume":"103","author":"Suarasan","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.yexcr.2021.112633_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071979","article-title":"I. Mijakovic, gold nanoparticles in diagnostics and therapeutics for human cancer","volume":"19","author":"Singh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2021.112633_bib20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ardp.201300188","article-title":"Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents","volume":"346","author":"Qin","year":"2013","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.yexcr.2021.112633_bib21","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1016\/j.bmcl.2016.10.028","article-title":"Syntheses, cytotoxic activity evaluation and HQSAR study of 1,2,3-triazole-linked isosteviol derivatives as potential anticancer agents","volume":"26","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.yexcr.2021.112633_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2014.11.008","article-title":"Design, synthesis and evaluation of novel 2-(1H-imidazole-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents","volume":"90","author":"Jiao","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.yexcr.2021.112633_bib23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/cpr.12296","article-title":"Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR\/VEGFR-2-mediated pathway in breast cancer","volume":"49","author":"Balakrishnan","year":"2016","journal-title":"Cell Prolif"},{"key":"10.1016\/j.yexcr.2021.112633_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112633_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/15384101.2020.1746490","article-title":"MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3","volume":"19","author":"You","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.yexcr.2021.112633_bib26","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.2174\/1381612820666140619123255","article-title":"SPARC in tumor pathophysiology and as a potential therapeutic target","volume":"20","author":"Feng","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.yexcr.2021.112633_bib27","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3892\/ol.2016.4399","article-title":"Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition","volume":"11","author":"Shi","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.yexcr.2021.112633_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bios.2014.05.035","article-title":"Quantum dots based molecular beacons for in vitro and in vivo detection of MMP-2 on tumor","volume":"61","author":"Li","year":"2014","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.yexcr.2021.112633_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbrc.2012.12.006","article-title":"c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1alpha","volume":"430","author":"Chen","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2021.112633_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030261","article-title":"Surface-initiated atom transfer polymerized anionic corona on gold nanoparticles for anti-cancer therapy","volume":"12","author":"Mao","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yexcr.2021.112633_bib31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1083\/jcb.201404140","article-title":"ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation","volume":"208","author":"Tornavaca","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.yexcr.2021.112633_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/1534735418775828","article-title":"Targeting VEGF\/VEGFRs pathway in the antiangiogenic treatment of human cancers by traditional Chinese medicine","volume":"17","author":"Zhang","year":"2018","journal-title":"Integr. Canc. Ther."},{"key":"10.1016\/j.yexcr.2021.112633_bib33","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1080\/10717544.2016.1199606","article-title":"Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles","volume":"23","author":"Tummala","year":"2016","journal-title":"Drug Deliv."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721001658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721001658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:36:28Z","timestamp":1757997388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482721001658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0014482721001658"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112633","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112633"}}